p166666. Sasaki M, Matsubara T, Kakuda Y, Sato Y, Nakanuma Y. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma. Am J Surg Pathol . 2014;38:364-9. doi:10.1097/PAS.0000000000000125. https://doi.org/10.1097/PAS.000000000000...
|
+ |
+ |
- |
CD56/N-CAM6767. Gütgemann I, Haas S, Berg JP, Zhou H, Büttner R, Fischer HP. CD56 expression aids in the differential diagnosis of cholangiocarcinomas and benign cholangiocellular lesions. Virchows Arch. 2006;448:407-11. doi:10.1007/s00428-005-0145-6. https://doi.org/10.1007/s00428-005-0145-...
|
+ |
+ |
+ |
EZH26666. Sasaki M, Matsubara T, Kakuda Y, Sato Y, Nakanuma Y. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma. Am J Surg Pathol . 2014;38:364-9. doi:10.1097/PAS.0000000000000125. https://doi.org/10.1097/PAS.000000000000...
|
- |
- |
+ |
p535050. Bickenbach K, Galka E, Roggin KK. Molecular mechanisms of cholangiocarcinogenesis: are biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile duct precursors to cholangiocarcinoma?. Surg Oncol Clin N Am . 2009;18:215-vii. doi:10.1016/j.soc.2008.12.001. https://doi.org/10.1016/j.soc.2008.12.00...
,6363. Lee KB. Histopathology of a benign bile duct lesion in the liver: Morphologic mimicker or precursor of intrahepatic cholangiocarcinoma. Clin Mol Hepatol. 2016;22:400-5. doi:10.3350/cmh.2016.0105. https://doi.org/10.3350/cmh.2016.0105...
|
- |
- |
+ |
BCL26565. Bertram S, Padden J, Kälsch J, Ahrens M, Pott L, Canbay A, et al. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. J Clin Pathol. 2016;69:619-26. doi: 10.1136/jclinpath-2015-203418. https://doi.org/10.1136/jclinpath-2015-2...
|
+ |
+ |
- (or faintly positive) |
HSP276565. Bertram S, Padden J, Kälsch J, Ahrens M, Pott L, Canbay A, et al. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. J Clin Pathol. 2016;69:619-26. doi: 10.1136/jclinpath-2015-203418. https://doi.org/10.1136/jclinpath-2015-2...
|
- |
+ (weak) |
+ (strong) |
HSP706565. Bertram S, Padden J, Kälsch J, Ahrens M, Pott L, Canbay A, et al. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. J Clin Pathol. 2016;69:619-26. doi: 10.1136/jclinpath-2015-203418. https://doi.org/10.1136/jclinpath-2015-2...
|
- |
+ (weak) |
+ (strong) |
STIP16565. Bertram S, Padden J, Kälsch J, Ahrens M, Pott L, Canbay A, et al. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. J Clin Pathol. 2016;69:619-26. doi: 10.1136/jclinpath-2015-203418. https://doi.org/10.1136/jclinpath-2015-2...
|
- |
+ |
+ |
SerpinH16565. Bertram S, Padden J, Kälsch J, Ahrens M, Pott L, Canbay A, et al. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. J Clin Pathol. 2016;69:619-26. doi: 10.1136/jclinpath-2015-203418. https://doi.org/10.1136/jclinpath-2015-2...
|
- |
- |
+ |
14-3-3Sigma6565. Bertram S, Padden J, Kälsch J, Ahrens M, Pott L, Canbay A, et al. Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. J Clin Pathol. 2016;69:619-26. doi: 10.1136/jclinpath-2015-203418. https://doi.org/10.1136/jclinpath-2015-2...
|
- |
+ |
+ |
Ki67 11. WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed.; vol. 1).,6969. Sasaki M, Sato Y, Nakanuma Y. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components. Histopathology. 2023;83:298-309. doi: 10.1111/his.14932. https://doi.org/10.1111/his.14932...
,7272. Tsokos CG, Krings G, Yilmaz F, Ferrell LD, Gill RM. Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma. Hum Pathol. 2016;57:61-7. doi:10.1016/j.humpath.2016.06.019. https://doi.org/10.1016/j.humpath.2016.0...
|
low |
low |
high (usually higher than 10%) |